UnknownNot Applicable

AMH for the Identification of PCOM in PCOS Diagnosis

Finland1,800 participantsStarted 2020-05-13

Plain-language summary

The purpose of this study is to validate the anti-müllerian hormone (AMH) cut-off established and validated in the APHRODITE study, for the determination of PCOM as part of the diagnosis of PCOS, using the Elecsys AMH Plus immunoassay.

Who can participate

Age range32 Years – 37 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female * Born July 1985-Dec 1987 in Northern Finland * Signed informed consent regarding ROCHE collaboration Exclusion Criteria: * Unwilling to undergo gynecological examination including transvaginal ultrasound (TVUS) * Unwilling to have blood drawn * Pregnancy

What they're measuring

The validation of the performance of the AMH cut-off, established in the APHRODITE study, to diagnose PCOM in the context of PCOS diagnosis.

Timeframe: Baseline

Trial details

NCT IDNCT05527353

SponsorOulu University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-10-31

Contact for this trial

Terhi T Piltonen, Professor

+358 8 3153051 terhi.piltonen@oulu.fi

View on ClinicalTrials.gov More Polycystic Ovary Syndrome trials